Fast Five Quiz: Multiple Myeloma Management

Joshua Richter, MD; Emmanuel C. Besa, MD


May 16, 2023

B-cell maturation antigen (BCMA) is the leading target for CAR-T therapy, which has been successful in the treatment of relapsed/refractory MM.

Antigen escape, the poor persistence of CAR-T cells, and the complicated tumor microenvironment remain a challenge to a significant population of MM patients who experience relapse after anti-BCMA CAR-T cell therapy. Broad clinical application of CAR-T cell therapy is also hampered by the high cost and time-consuming nature of the manufacturing processes. There are several potential strategies under investigation to overcome these challenges.

In patients with relapsed or refractory MM, the use of a bispecific antibody that binds to both BCMA and CD3 to redirect T cells to MM cells shows promising efficacy. Other potential targets either for single-target or dual-target CAR-T are also being studied.

Learn more about antibody-drug conjugates in MM.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.